ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology will enable academic and pharmaceutical researchers to specifically measure only the active form of plasmin, a protease associated with fibrinolysis. It is believed that plasmin is involved in the pathogenesis of lung disorders such as idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). Plasmin activity is also dysregulated in several other disease states, including pre-eclampsia, nephrotic syndrome and diabetes mellitus. The registration of a CE Mark indicates that the ProteaseTag® Active Plasmin Immunoassay complies with EU legislation, and the company will immediately commercialise the Immunoassay through its existing network of respiratory contacts across Europe.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “This is the third product for which ProAxsis has been able to register a CE Mark, and we’re delighted to add the ProteaseTag® Active Plasmin Immunoassay to our existing portfolio of products. We’re very grateful for the support we’ve received from Invest Northern Ireland for this project. As well as being a useful research tool, Plasmin continues to interest pharmaceutical companies as a potential therapeutic target in a range of different diseases. We expect to present data on this new assay at a major respiratory conference in the second half of the year, and look forward to expanding our range of products to enable the measurement of the active form of additional proteases during 2018.”
Any queries concerning ProAxsis’ Immunoassay for measuring active plasmin, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to firstname.lastname@example.org.